# Cytotoxic Homoisoflavonoids from the Bulbs of *Bellevalia flexuosa*

By: Tamam El-Elimat, José Rivera-Chávez, Joanna E. Burdette, Austin Czarnecki, Maram B. Alhawarri, Mohammad Al-Gharaibeh, Feras Alali, and Nicholas H. Oberlies

**Made available courtesy of Elsevier: https://doi.org/10.1016/j.fitote.2018.02.022**

## Abstract:

Four new homoisoflavonoids, 7-*O*-methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin (**4**), 6-hydroxy-8-demethoxy-4′-*O*-methyl-3,9-dihydropunctatin (**8**), 7,4′-*O*-dimethyl-8-demethoxy-3,3′-dihydroxy-3,9-dihydropunctatin (**13**), and 7-*O*-methyl-3-hyroxy-3,9-dihydropunctatin (**14**) were identified from a chloroform extract of the bulbs of *Bellevalia flexuosa*, along with 13 known analogues. The structures were determined by analysis of HRMS and NMR data, while ECD spectroscopy enabled the assignment of the absolute configurations of the new compounds **4**, **8**, **13** and **16**. The cytotoxic activities of the isolated compounds (**1**–**17**) were evaluated using a panel of human cancer cell lines. Compounds **2** and **7** were the most potent against the MDA-MB-435 (melanoma) cancer cell line with IC$_{50}$ values of 1.6 and 2.0 μM, respectively, and were essentially equipotent against the OVCAR3 (ovarian) cancer cell line with IC$_{50}$ values of 9.5 and 10.8 μM, respectively. However, compound **7**, with an IC$_{50}$ value of 3.6 μM, was the most potent against the MDA-MB-231 (breast) cancer cell line.

**Keywords:** Homoisoflavonoids | *Bellevalia* | Bulbs | Absolute configuration | Cytotoxicity | Human cancer cell lines

## Article:

### 1. Introduction

Homoisoflavonoids are a rare subclass of flavonoids possessing an extra carbon atom in their skeleton [1, 2, 3, 4, 5]. Biosynthetically, chalcones are thought to be the precursors of homoisoflavonoids [3]. Currently, about 250 natural homoisoflavonoids have been reported in the literature, with the majority being isolated from several genera of Asparagaceae and Fabaceae [1, 2, 3, 4, 6, 7]. Based on their structures, homoisoflavonoids have been classified into five groups: 3-benzyl-4-chromanones, 3-benzyl-3-hydroxy-4-chromanones, 3-benzylidene-4-

chromanones (*E* or *Z*), 3-benzylchrom-2-en-4-ones, and the scillascillins [4]. Homoisoflavonoids have attracted attention because of their various biological activities, including antioxidant, anti-inflammatory, antimutagenic, antimicrobial, antiallergic and antihistaminic, anti-diabetic, cytotoxic, and anti-angiogenic effects, as well as protein tyrosine kinase inhibition activity [3,4].

Although Jordan is a small country of about 96,188 km$^2$, it has a remarkable diversity of wildlife, which could be attributed to its unique location at the intersection of three continents, encapsulating four bio-geographical zones: Mediterranean, Irano-Turanian, Saharo-Arabian, and Tropical (Sudanian penetration) [8, 9, 10]. Within these different zones, thirteen vegetation types are identified, reflecting Jordan's diverse landscape, climate, and geology [8,11]. >2600 vascular plant species belonging to 113 family and 810 genera are reported to grow in the wild, of which 100 are endemic and >70 species are considered extinct [8]. Hence, studies of Jordan's wild plants have been initiated [12, 13, 14] as a potential source of drug leads.

In the current study, the bulbs of *Bellevalia flexuosa* Boiss. (Asparagaceae) have been explored. *B. flexuosa*, which is known as "Common Roman Squill", and in Jordan as "Drooping Onion" [15], is one of eleven species that are reported by Al-Eisawi to grow in Jordan in the wild [16]. Although no medical use is reported for this plant species by the local people of Jordan, a closely related species (*B. eigii*) was investigated recently, yielding a set of homoisoflavoinids [6]. *B. flexuosa* is a perennial herb with underground bulbs that is found flowering from February to March. It flourishes in mountains and waste grounds [16]. Chemical investigation of the chloroform extract of the bulbs of *B. flexuosa* resulted in the isolation and identification of seventeen homoisoflavonoids; of which thirteen were known (**1–3**, **5–7**, **9–12**, and **15–17**) and four were new analogues: 7-*O*-methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin (**4**), 6-hydroxy-8-demethoxy-4′-*O*-methyl-3,9-dihydropunctatin (**8**), 7,4′-*O*-dimethyl-8-demethoxy-3,3′-dihydroxy-3,9-dihydropunctatin (**13**), and 7-*O*-methyl-3-hyroxy-3,9-dihydropunctatin (**14**). ECD spectroscopy was used to assign the absolute configurations of the new compounds **4**, **8**, **13**, and **14**. Homoisoflavonoids were reported to have a broad range of biological activities, including cytotoxic effects [3]. Therefore, the isolated compounds (**1–17**) were tested for their cytotoxicity using three human cancer cell lines, namely MDA-MB-435 (melanoma), MDA-MB-231 (breast), and OVCAR3 (ovarian).

## 2. Experimental

### 2.1. General experimental procedures

Optical rotations, UV data, and ECD spectra were obtained using a Rudolph Research Autopol III polarimeter (Rudolph Research Analytical), a Varian Cary 100 Bio UV–vis spectrophotometer (Varian Inc.), and an Olis DSM 17 ECD spectrophotometer (Olis, Inc.). NMR data were collected using either a JEOL ECA-500 NMR spectrometer operating at 500 MHz for $^1$H and 125 MHz for $^{13}$C (JEOL Ltd.) or an Agilent 700 MHz NMR spectrometer (Agilent Technologies), equipped with a cryoprobe, operating at 700 MHz for $^1$H and 175 MHz for $^{13}$C. Residual solvent signals were utilized for referencing. HRMS data were acquired using a Thermo QExactive Plus mass spectrometer equipped with an electrospray ionization source (Thermo Fisher Scientific). Gemini–NX C$_{18}$ analytical (5 μm; 250 × 4.6 mm) and preparative (5 *μ*m; 250 × 21.2 mm) columns (both from Phenomenex) along with Atlantis T3 C$_{18}$ analytical (5 *μ*m;

250 × 4.6 mm) and semipreparative (5 $\mu$m; 250 × 10.0 mm) columns (both from Waters Corp.) were used on a Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector (PDA), with data collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2, Varian Inc.). Flash chromatography was performed on a Teledyne ISCO CombiFlash Rf 200 using Silica Gold columns (both from Teledyne Isco) and monitored by UV and evaporative light-scattering detectors. All other reagents and solvents were obtained from Fisher Scientific and were used without further purification.

## 2.2. Plant material

Bulbs of *B. flexuosa* were collected by Mohammad Bashabshah during flowering stage from the campus of the Jordan University of Science and Technology (JUST), Irbid, Jordan in March/April 2016. The plant material was identified by Mohammad Al-Gharaibeh, Plant Taxonomist, Faculty of Agriculture, JUST. A voucher specimen (PHS-122) was deposited in the herbarium of the Faculty of Pharmacy, JUST. The bulbs were cleaned of mud, sliced into small pieces, and air dried at rt. in a well-ventilated area.

## 2.3. Extraction and isolation

Air-dried bulbs of *B. flexuosa* were ground to a powder using a laboratory mill. The powdered bulbs (850 g) were extracted exhaustively with $CHCl_3$ by soaking at rt. The solvent was evaporated under reduced pressure to yield the $CHCl_3$ extract (3.1 g), which was reconstituted in a 500 mL mixture of 5:4:1 $H_2O$:$CHCl_3$:MeOH. The mixture was stirred for 30 min and left to separate in a separatory funnel. The organic layer was collected and evaporated to dryness under reduced pressure. The dried organic extract was reconstituted in 200 mL of 1:1 MeOH:$CH_3CN$ and 200 mL of hexanes and transferred into a separatory funnel. The biphasic solution was shaken vigorously. The MeOH/MeCN layer was evaporated to dryness under vacuum. The dried MeOH/$CH_3CN$ layer (2.1 g) was dissolved in $CHCl_3$ and mixed with Celite 545. Normal-phase flash chromatography was run using a gradient solvent system of hexanes-$CHCl_3$-MeOH, at a flow rate of 35 mL/min, and column volumes of 41.3 over a total run time of 30.7 min, to yield seven fractions. Fraction 3 (267.9 mg) was subjected to preparative HPLC over a Gemini column using a gradient system of 50:50 to 60:40 of MeOH-$H_2O$ (0.1% formic acid) over 30 min at a flow rate of 20 mL/min to yield 8 subfractions, of which subfraction 3 was identified as compound **15** (2.1 mg). Subfraction 7 (1.9 mg) was subjected to semipreparative HPLC purification over Atlantis T3 column using a gradient solvent system of 40:60 to 50:50 $CH_3CN$-$H_2O$ (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min to yield compounds **5** (0.7 mg) and **13** (0.4 mg). Subfraction 8 (8.3 mg) was subjected to semipreparative HPLC using Atlantis T3 column and a gradient solvent system of 40:60 to 60:40 $CH_3CN$-$H_2O$ (0.1% formic acid) over 20 min at a flow rate of 4.6 mL/min to yield compounds **7** (5.4 mg) and **13** (0.3 mg).

Fraction 4 (544.7 mg) was subjected to preparative HPLC over a Gemini column using a gradient system of 60:40 to 70:30 of MeOH-$H_2O$ (0.1% formic acid) over 20 min at a flow rate of 21.2 mL/min to yield compound **5** (335.6 mg).

Fraction 5 (116.0 mg) was subjected to preparative HPLC over a Gemini column using a gradient system of 50:50 to 70:30 of MeOH-H$_2$O (0.1% formic acid) over 20 min at a flow rate of 21.2 mL/min to yield seven sub-fractions. Further HPLC purificaton of subfractions 3 (3.4 mg) and 4 (3.2 mg) using semipreparative HPLC (Atlantis T3 column) and a gradient solvent systems of 40:60 to 50:50 CH$_3$CN-H$_2$O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min yielded compounds **17** (1.3 mg) and **2** (2.1 mg) from subfractions 3 and 4, respectively. Subfractions 6 (2.2 mg) and 7 (14.3 mg) were purified using semipreparative HPLC (Atlantis T3 column) and a gradient solvent system of 40:60 to 60:40 CH$_3$CN-H$_2$O (0.1% formic acid) over 20 min at a flow rate of 4.6 mL/min to yield compounds **4** (0.9 mg) and **16** (10.8 mg) from subfractions 6 and 7, respectively.

Fraction 6 (379.3 mg) was purified using preparative HPLC (Gemini column) and a gradient solvent system of 50:50 to 55:45 of MeOH-H$_2$O (0.1% formic acid) over 20 min, hold for 5 min and then increasing to 60:40 over 10 min at a flow rate of 21.2 mL/min to yield 5 subtractions. Subfraction 1 (13.2 mg) was further purified using semipreparative (Atlantis T3 column) and a gradient solvent system of 30:70 to 40:60 CH$_3$CN-H$_2$O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min to yield compound **8** (2.3 mg) and another subfraction that was further purified using semipreaprative HPLC method over Atlantis T3 column and an isocratic solvent system of 28:72 CH$_3$CN-H$_2$O (0.1% formic acid) for 50 min at a flow rate of 4.6 mL/min to yield compounds **9** (2.3 mg) and **14** (1.9 mg). Subfractions 2 (15.6 mg) and 3 (39.0 mg) were purified using semipreparative HPLC (Atlantis T3 column) and a gradient solvent systems of 40:60 to 60:50 CH$_3$CN-H$_2$O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min to yield compound **6** (9.1 mg) from subfraction 2 and compounds **3** (1.4 mg), **6** (1.9 mg), and **10** (19.2 mg) from subfraction 3. Subfractions 4 (3.4 mg) and 5 (3.8 mg) were purified using semipreparative HPLC (Atlantis T3 column) and gradient solvent systems of 40:60 to 50:50 CH$_3$CN-H$_2$O (0.1% formic acid) over 15 min at a flow rate of 4.6 mL/min to yield compounds **1** (0.5 mg) and **10** (0.5 mg) from fraction 4 and compounds **2** (0.9 mg), **5** (2.3 mg), **11** (0.9 mg), and **12** (1.5 mg) from subfraction 5.

### 2.3.1. 7-O-Methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin (4)

Yellowish oil; $[\alpha]_D^{28}$ − 27 (c 0.1, MeOH)]; UV (MeOH) $\lambda_{max}$ (log $\varepsilon$) 334 (3.23), 288 (3.98), 220 (3.94) nm; ECD (c $0.9 \times 10^{-4}$ M, MeOH) $\lambda$ ($\Delta\varepsilon$) 244 (+0.68) nm, 269 (+0.96) nm, 295 (−2.07), 320 (+0.18) nm (Fig. 3); HRESIMS m/z 317.1016 [M + H]$^+$ (calcd for C$_{17}$H$_{17}$O$_6$, 317.1020).

### 2.3.2. 6-Hydroxy-8-demethoxy-4′-O-methyl-3,9-dihydropunctatin (8)

Light yellow amorphous powder; $[\alpha]_D^{28}$ − 36 (c 0.1, MeOH)]; UV (MeOH) $\lambda_{max}$ (log $\varepsilon$) 360 (3.32), 291 (4.05), 242 (3.94), 229 (3.99) nm; ECD (c $0.9 \times 10^{-4}$ M, MeOH) $\lambda$ ($\Delta\varepsilon$) 260 (+2.02) nm, 293 (−4.79), 323 (+0.50) nm (Fig. 3); HRESIMS m/z 317.1016 [M + H]$^+$ (calcd for C$_{17}$H$_{17}$O$_6$, 317.1020).

### 2.3.3. 7,4′-O-dimethyl-8-demethoxy-3,3′-dihydroxy-3,9-dihydropunctatin (13)

White amorphous powder; $[\alpha]_D^{28} - 96$ ($c$ 0.05, MeOH)]; UV (MeOH) $\lambda_{max}$ (log $\varepsilon$) 334 (3.35), 288 (4.08), 218 (4.10) nm; ECD ($c$ 0.9 × 10$^{-4}$ M, MeOH) $\lambda$ ($\Delta\varepsilon$) 253 (+1.80) nm, 295 (−3.52), 320 (−0.53) nm (Fig. 3); HRESIMS $m/z$ 347.1122 [M + H]$^+$ (calcd for $C_{18}H_{19}O_7$, 347.1125).

### 2.3.4. 7-*O*-methyl-3-hyroxy-3,9-dihydropunctatin (14)

Light yellow amorphous powder; $[\alpha]_D^{28} - 170$ ($c$ 0.1, MeOH)]; UV (MeOH) $\lambda_{max}$ (log $\varepsilon$) 348 (3.58), 292 (4.15), 224 (4.15) nm; ECD ($c$ 0.9 × 10$^{-4}$ M, MeOH) $\lambda$ ($\Delta\varepsilon$) 265 (+4.16) nm, 292 (−4.53), 313 (+0.42) nm (Fig. 3); HRESIMS $m/z$ 347.1124 [M + H]$^+$ (calcd for $C_{18}H_{19}O_7$, 347.1125).

### 2.4. Cytotoxicity assay

Compounds (**1–17**) were tested for cytotoxicity against human melanoma cancer cells MDA-MB-435 [17], human breast cancer cells MDA-MB-231, and human ovarian cancer cells OVCAR3 as described previously [18,19]. Briefly, the cell lines were propagated at 37 °C in 5% $CO_2$ in RPMI 1640 medium, supplemented with fetal bovine serum (10%), penicillin (100 units/mL), and streptomycin (100 µg/mL). Cells in log phase growth were harvested by trypsinization followed by two washings to remove all traces of enzyme. A total of 5000 cells were seeded per well of a 96-well clear, flat-bottom plate (Microtest 96®, Falcon) and incubated overnight (37 °C in 5% $CO_2$). Samples dissolved in DMSO were then diluted and added to the appropriate wells. The cells were incubated in the presence of test substance for 72 h at 37 °C and evaluated for viability with a commercial absorbance assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega Corp, Madison, WI) that measured viable cells. IC$_{50}$ values are expressed in µM relative to the solvent (DMSO) control. Taxol was used as a positive control.



|     | R₁ | R₂ | R₃ | R₄ | R₅ |
| --- | --- | --- | --- | --- | --- |
| **1:** | H | H | H | H | H |
| **2:** | H | H | H | OH | CH₃ |
| **3:** | H | H | OCH₃ | H | H |
| **4:** | H | CH₃ | H | OH | H |
| **5:** | H | CH₃ | OCH₃ | H | H |
| **6:** | H | CH₃ | OH | H | H |
| **7:** | H | CH₃ | OCH₃ | OH | CH₃ |
| **8:** | OH | H | H | H | CH₃ |
| **9:** | OH | CH₃ | OCH₃ | H | H |
| **10:** | OH | CH₃ | OCH₃ | OH | H |
| **11:** | OCH₃ | CH₃ | OCH₃ | H | H |

|     | R₁ | R₂ | R₃ |
| --- | --- | --- | --- |
| **12:** | H | H | H |
| **13:** | H | OH | CH₃ |
| **14:** | OCH₃ | H | H |

Fig. 1. Structures of compounds **1–17**.

## 3. Results and discussion

Air-dried bulbs of *B. flexuosa* were extracted with $CHCl_3$, and the resulting crude extract was reconstituted in a mixture of 5:4:1 $H_2O$:$CHCl_3$:MeOH. The dried organic extract was reconstituted in 1:1 MeOH/$CH_3CN$ and then defatted using hexanes. The resulting dried MeOH/$CH_3CN$ extract was fractionated using normal phase flash chromatography. HPLC methods, preparative and semipreprative, were used for purifications of the fractions leading to the isolation of seventeen homoisoflavonoids (**1–17**) (Fig. 1).

The structures of thirteen known homoisoflavonoids analogues (**1–3**, **5–7**, **9–12**, and **15–17**) were established by comparison of NMR (1D/2D), HRMS, and ECD data with literature values and were identified as: 4′,5,7-trihydroxyhomoisoflavanone (**1**) [6], 3′-hydroxy-3,9-dihydroeucomin (**2**) [6], 3,9-dihydropunctatin (**3**) [20], 7-*O*-methyl-3,9-dihydropunctatin (**5**) [6], 8-*O*-demethyl-7-*O*-methyl-3,9-dihydropunctatin (**6**) [6], 7,4′-di-*O*-methyl-3′-hydroxy-3,9-dihydropunctatin (**7**) [6], 6-hydroxy-7-*O*-methyl-3,9-dihydropunctatin (**9**) [6], 7-*O*-methyl-3′-hydroxypunctatin (**10**), 3-(4-hydroxybenzyl)-5-hydroxy-6,7,8-trimethoxychroman-4-one (**11**) [21], 7-*O*-methyl-8-demethoxy-3-hydroxy-3,9-dihydropunctatin (**12**) [6], 5-hydroxy-7,8-dimethoxychroman-4-one (**15**) [6], 7-*O*-methylpunctatin (16) [6], and isomuscomosin (**17**) [6], (Figs. **S1-S3**, **S5-S7**, **S9-S12**, **S15-S17**, Supplementary Data).

Compound **4** (0.93 mg) was isolated as a yellowish oil with a molecular formula of $C_{17}H_{16}O_6$ (10 degrees of unsaturation) as determined by HRESIMS (*m/z* 317.1016 $[M + H]^+$, calcd. 317.1020), which was further supported by $^1H$, $^{13}C$, and edited HSQC NMR data (Table 1, Table 2, Fig. S4, Supplementary Data). Compound **4** showed characteristic NMR signals indicative of a 3-benzylchroman-4-one homoisoflavonoid analogue with very high structural similarity to **2**, both sharing the same molecular formula. HMBC data analysis indicated the structure of **4** to be different from that of **2** by the methylation position. HMBC correlations from $H_3$–7′ ($\delta_H$ 3.88, s) to C-4′ ($\delta_C$ 145.5) in **2** and from $H_3$–10 ($\delta_H$ 3.81, s) to C-7 ($\delta_C$ 168.0) in **4** enabled the assignment of **2** as a 4′-*O*-methyl analogue and **4** as a 7-*O*-methyl analogue. In the latter, HMBC correlations from H-8 ($\delta_H$ 5.97, d, *J* = 2.3) to C-4a ($\delta_C$ 102.7), C-6 ($\delta_C$ 95.1), C-7 ($\delta_C$ 168.0), and C-8a ($\delta_C$ 163.0); from H-6 ($\delta_H$ 6.06, d, *J* = 2.3) to C-5 ($\delta_C$ 164.6), C-7, C-8 ($\delta_C$ 94.0), and C-4a, from 5-OH ($\delta_H$ 12.11, s) to C-4a, C-5, and C-6 established the substitution pattern of ring A. In addition, HMBC correlations from H-2′ ($\delta_H$ 6.75, d, *J* = 1.3) to C-9 ($\delta_C$ 32.3), C-4′ ($\delta_C$ 142.4), and C-6′ ($\delta_C$121.8); from H-5′ ($\delta_H$ 6.81, d, *J* = 7.9) to C-1′ ($\delta_C$ 131.0) and C-3′ ($\delta_C$ 143.8); from H-6′ ($\delta_H$6.66, dd, *J* = 7.9, 1.3) to C-9, C-2′ ($\delta_C$ 116.3), and C-4′ established the substitution pattern of ring C. Further examination of the 2D NMR data established the structure of **4** (Fig. 2) as 7-*O*-methyl-8-demethoxy-3′-hydroxy-3,9-dihydropunctatin. The absolute configurations of 3-benzylchroman-4-one-type homoisoflavonoids are assigned using electronic circular dichroism (ECD) spectroscopy [22], in which a negative Cotton effect in the 287–295 nm region of the ECD curves is indicative of a 3*R* configuration [22]. Compound **4** showed a negative Cotton effect at 295 nm ($\Delta\varepsilon$ = −2.07) in the ECD spectrum, supporting an *R*-configuration at C-3 (Fig. 3).

**Table 1.** $^1$H NMR data for compounds **4**, **8**, **13**, and **14** (500 MHz in CDCl$_3$)$^a$.

| position | 4 | 8 | 13 | 14 |
|---|---|---|---|---|
| 2 | 4.12, dd (11.4, 7.1) | 4.08, dd (11.4, 7.1) | 4.06, d (11.2) | 4.09, d (11.2) |
|  | 4.28, dd (11.4, 4.1) | 4.25, dd (11.4, 4.1) | 4.23, d (11.2) | 4.36, d (11.2) |
| 3 | 2.80, m | 2.78, m |  |  |
| 6 | 6.06, d (2.3) |  | 6.11, d (2.3) | 6.16, s |
| 8 | 5.97, d (2.3) | 6.05, s | 6.05, d (2.3) |  |
| 9 | 2.65, dd (13.9, 10.4) | 2.69, dd (13.8, 10.6) | 2.89, d (13.8) | 2.94, d (14.1) |
|  | 3.12, dd (13.9, 4.5) | 3.16, dd (13.8, 4.5) | 2.93, d (13.8) | 2.98, d (14.1) |
| 10 | 3.81, s |  | 3.85, s | 3.91, s |
| 11 |  |  | 3.88, s | 3.83, s |
| 12 |  | 3.91, s |  |  |
| 2' | 6.75, d (1.3) | 7.08, d (8.5) | 6.82, d (2.1) | 7.04, d (8.5) |
| 3' |  | 6.78, d (8.5) |  | 6.75, d (8.5) |
| 5' | 6.81, d (7.9) |  | 6.76, d (8.1) |  |
| 6' | 6.66, dd (7.9, 1.3) |  | 6.65, dd (8.1, 2.1) |  |
| 3-OH |  |  | 3.36, s |  |
| 5-OH | 12.11, s | 11.78, s | 11.25, s | 11.21, s |
| 6-OH |  | 5.03, br. s |  |  |
| 7-OH |  | 4.81, br. s |  |  |
| 3'-OH | 5.20 or 5.33$^b$, br. s |  | 5.58, s |  |
| 4'-OH | 5.20 or 5.33$^b$, br. s |  |  | 4.83, br. s |

$^a\delta$ in ppm, mult ($J$ in Hz); $^b$Could be swapped.

**Table 2.** $^{13}$C NMR data for **4**, **8**, **14** (125 MHz), and for **13** (175 MHz) in CDCl$_3$.

| position | 4 | 8 | 13 | 14 |
|---|---|---|---|---|
| 2 | 69.1 | 69.4 | 71.9 | 72.5 |
| 3 | 46.9 | 47.2 | 72.3 | 72.2 |
| 4 | 198.0 | 198.8 | 198.3 | 198.6 |
| 4a | 102.7 | 102.5 | 100.6 | 100.4 |
| 5 | 164.6 | 148.2 | 164.1 | 160.0 |
| 6 | 95.1 | 156.1 | 95.5 | 93.7 |
| 7 | 168.0 | 127.4 | 168.8 | 162.3 |
| 8 | 94.0 | 91.1 | 94.6 | 129.9 |
| 8a | 163.0 | 154.8 | 162.9 | 153.5 |
| 9 | 32.3 | 32.1 | 41.0 | 40.9 |
| 10 | 55.8 |  | 56.0 | 56.6 |
| 11 |  |  | 56.0 | 61.7 |
| 12 |  | 56.5 |  |  |
| 1' | 131.0 | 130.1 | 127.3 | 126.2 |
| 2' | 116.3 | 130.5 | 116.8 | 131.9 |
| 3' | 143.8 | 115.7 | 145.4 | 115.4 |
| 4' | 142.4 | 154.5 | 145.9 | 155.0 |
| 5' | 115.7 |  | 110.5 |  |
| 6' | 121.8 |  | 122.2 |  |

**Fig. 2.** Key COSY and HMBC correlations of **4**, **8**, **13**, and **14**.



**Fig. 3.** ECD spectra for compounds A) **4**, B) **8**, C) **13**, and D) **14** [0.09 mM, MeOH, cell length 2 cm].

HRESIMS and NMR data of compound **8** (2.3 mg), which was obtained as a yellow amorphous powder, revealed its molecular formula as $C_{17}H_{16}O_6$ ($m/z$ 317.1016 [M + H]$^+$, calcd 317.1020) (Table 1, Table 2, Fig. S8, Supplementary Data). As in compound **4**, the NMR data of **8** showed

characteristic signals indicative of a 3-benzylchroman-4-one-type homoisoflavonoid with structural similarity to **3** as they shared the same molecular formula. However, the 8-methoxy group of ring A ($\delta_H/\delta_C$ 3.95/61.7 for $H_3$–11/C-11) in **3** was replaced by an aromatic proton singlet ($\delta_H/\delta_C$ 6.05/91.1 for H-8/C-8) in **8**. In addition, the aromatic proton singlet ($\delta_H/\delta_C$ 6.13/96.0 for H-6/C-6) in **3** was replaced by an exchangeable proton singlet ($\delta_H$ 5.03 for 6-OH) in **8**. Moreover, the exchangeable proton singlet in **3** ($\delta_H$ 4.75 for 4′-OH) was replaced by a methyl group ($\delta_H/\delta_C$ 3.91/56.5 for $H_3$–7′/C-7′). The structure of **8** was inferred by further analysis of HMBC data. HMBC correlation from H-8 to C-4 (198.8), C-4a (102.5), C-6 (156.1), and C-8a (154.8) established the substitution pattern of ring A, while the HMBC correlation from $H_3$–7′ ($\delta_H$ 3.91, s) to C-4′ ($\delta_C$ 154.5) confirmed the methylation position in **8**. Further analysis of the 2D NMR data established the structure of **8** to which the trivial name 6-hydroxy-8-demethoxy-4′-$O$-methyl-3,9-dihydropunctatin was assigned (Fig. 2). A negative Cotton effect at 293 nm in the ECD spectrum of compound **8** ($\Delta\varepsilon = -4.79$) indicated an $R$-configuration at C-3 (Fig. 3).

Compound **13** (0.66 mg) was obtained as a white amorphous powder. HRESIMS ($m/z$ 347.1122 $[M + H]^+$, calcd 347.1125) NMR data indicated a molecular formula of $C_{18}H_{18}O_7$ (Table 1, Table 2, Fig. S13, Supplementary Data). The NMR data indicated compound **13** as a 3-benzyl-3-hydroxychroman-4-one homoisoflavonoid analogue. The compound showed high structural similarity to **12**. However, compound **13** showed a methoxy group, as indicated by ^{1}H and ^{13}C NMR data ($\delta_H/\delta_C$ 3.88/56.0) and a hydroxyl group at $\delta_H$ 5.58 (3'-OH) consistent with the 30 amu difference in the HRMS data of **13** relative to **12**. The aromatic $A_2B_2$ system of ring B in **12** was replaced by an ABM spin system in **13** ($\delta_H$ 6.82, d, $J = 2.1$; 6.76, d, $J = 8.1$; and 6.65, dd, $J = 8.1$, 2.1, for H-2′, H-5′, and H-6′, respectively), indicating the presence of a 1,3,4-trisubstituted benzene ring. An HMBC correlation from the 4′-$OCH_3$ protons to C-4′ ($\delta_C$ 145.9) confirmed its connectivity. The structure of compound **13** was deduced by further inspection of the 2D NMR data, including COSY and HMBC spectra (Fig. 2). Compound **13** was given the trivial name 7,4′-$O$-dimethyl-8-demethoxy-3,3′-dihydroxy-3,9-dihydropunctatin. A negative Cotton effect ($\Delta\varepsilon = -3.52$) at 297 nm of the ECD spectrum of **13** indicated an $S$-configuration at C-3 (Fig. 3) [22].

The HRESIMS ($m/z$ 347.1124 $[M + H]^+$, calcd 347.1125) and NMR data of compound **14** (2.38 mg), which was obtained as a light yellow amorphous powder, indicated a molecular formula of $C_{18}H_{18}O_7$ (Table 1, Table 2, Fig. S14, Supplementary Data). The NMR data of **14** showed distinctive peaks indicative of a 3-benzyl-3-hydroxychroman-4-one homoisoflavonoid analogue. The compound showed high structural similarity to **12**. However, compound **14** had an extra methoxy group, as indicated by ^{1}H and ^{13}C NMR data ($\delta_H/\delta_C$ 3.83/61.7), consistent with the 30 amu difference in the HRMS data of **14** relative to **12**, replacing the aromatic doublet ($\delta_H$ 6.05, d, $J = 2.1$ for H-8) in **12**. HMBC correlations from H-6 to C-4 (198.6), C-4a (100.4), C-5 (160.0), C-7 (162.3), and C-8 (129.9) confirmed the substitution pattern of ring A. The structure of compound **14** was deduced by further inspection of the 2D NMR data, including COSY and HMBC spectra (Fig. 2). Compound **14** was given the trivial name 7-$O$-methyl-3-hyroxy-3,9-dihydropunctatin. A negative cotton effect ($\Delta\varepsilon = -4.53$) at 292 nm in the ECD spectrum of **14** was indicative of an $S$-configuration at C-3 (Fig. 3) [22].

Compounds (**1**–**17**) were evaluated for their cytotoxic activities against the MDA-MB-435 (melanoma), MDA-MB-231 (breast), and OVCAR3 (ovarian) cancer cell lines. Compounds **2** and **7** were the most potent on the three cancer cell lines with $IC_{50}$ values of 1.6, 14.2, 9.5 and 2.0, 3.6, and 10.8 μM, respectively (Table 3). Compound **2** was reported to be active against colon cancer (HT-29 cell line $ED_{50} = 2.78$ μM) and breast cancer (MDA-MB-435 cell line $ED_{50} = 1.33$ μM). Compounds **2** and **7** were reported previously by our group to be active against breast cancer (MDA-MB-435 cell line) with $IC_{50}$ values of 1.0 and 1.1 $\mu M$, respectively [6]. Moreover, compound **7** showed moderate activity when tested against colon cancer (HT-29 cell line $IC_{50} = 17.3$ $\mu M$) [6]. The cytotoxicity data of the new and known analogues isolated in the current work expanded our understanding of the structure-activity relationships of this unique class of flavonoids. The substitution pattern of ring B affects the activity significantly. Compound **1**, with a 4′-OH group, was inactive. However, compound **4**, with 3′,4′-dihydroxy substituents, showed $IC_{50}$ values of 14.3, 17.5, and 24.8 $\mu M$ against the MDA-MB-435, MDA-MB-231, and OVCAR3 cancer cell lines, respectively. Moreover, reducing the polarity of the ring B substituents results in improved cytotoxic activity. For example, the activity of compound **2**, with a 4′-methoxy substituent, increased by ~9- and 3-folds the activity against MDA-MB-435 and OVCAR3 cancer cell lines in comparison with compound **4** via $IC_{50}$ values of 1.6 and 9.5 μM, respectively. Similarly, although compound **10** was inactive, compound **7**, with a 4′-methoxy substituent, showed $IC_{50}$ values of 2.0, 3.6, and 10.8 $\mu M$ against the MDA-MB-435, MDA-MB-231, and OVCAR3 cancer cell lines, respectively. The same pattern can be noticed when comparing the cytotoxic activities of compounds **12** and **13**. Compound **12** with a 4′-OH substituent was inactive, however compound **13**, with 3′-hydroxy and 4′-methoxy substituents, showed activity against the MDA-MB-435 cancer cell line with $IC_{50}$ value of 14.4 $\mu M$. In addition, introducing an OH group at C-3 increases the activity significantly, although compound **5** was inactive, compound **14**, with a 3-OH substituent, showed $IC_{50}$ value of 15.2 $\mu M$ against the MDA-MB-435 cancer cell line.

**Table 3.** Cytotoxic activities of compounds **2**, **4**, **7**, **13**, and **14**.

| compound[a] | $IC_{50}$ values in μM[b] | | |
|---|---|---|---|
| | MDA-MB-435 | Ovcar3 | MDA-MB-231 |
| **2** | 1.6 | 14.2 | 9.5 |
| **4** | 14.3 | 17.5 | 24.8 |
| **7** | 2.0 | 3.6 | 10.8 |
| **13** | 14.4 | >25 | >25 |
| **14** | 15.2 | >25 | >25 |
| **Taxol**[c] | 0.0001 | 0.0015 | 0.17 |

[a]Compounds **1**, **3**, **5**, **6**, **8**–**12**, **15**–**17** were inactive, $IC_{50}$ values >25 μM. [b]$IC_{50}$ is the concentration to inhibit 50% of growth with a 72 h incubation. [c]Positive control.

## Conflict of interest

All the authors have no conflict of interest.

## Acknowledgments

CA125066 from the National Cancer Institute/National Institutes of Health, Bethesda, MD, USA.

## References

[1] B.M. Abegaz, J. Mutanyatta-Comar, M. Nindi, Naturally occurring homoisoflavonoids: Phytochemistry, biological activities and synthesis, Nat. Prod. Commun. 2 (2007) 475‑498.

[2] W. Heller, C. Tamm, Homoisoflavanones and Biogenetically Related Compounds, in: P.A. Cadby, R.G. Cooke, J.M. Edwards, W. Heller, C.W. Jefford, E. Lederer, P. Lefrancier, S. Dev, C. Tamm, W. Herz, H. Grisebach, G.W. Kirby (Eds.), Fortschritte Der Chemie Organischer Naturstoffe / Progress in the Chemistry of Organic Natural Products, Springer Vienna, Vienna, 1981, pp. 105‑152.

[3] L.-G. Lin, Q.-Y. Liu, Y. Ye, Naturally occurring homoisoflavonoids and their pharmacological activities, Planta Med. 80 (2014) 1053‑1066.

[4] D.A. Mulholland, S.L. Schwikkard, N.R. Crouch, The chemistry and biological activity of the Hyacinthaceae, Nat. Prod. Rep. 30 (2013) 1165‑1210.

[5] M.I. Calvo, Three new homoisoflavanones from the bulbs of Ledebouria floribunda, Fitoterapia 80 (2009) 394‑398.

[6] F. Alali, T. El-Elimat, H. Albataineh, Q. Al-Balas, M. Al-Gharaibeh, J.O. Falkinham 3rd, W.L. Chen, S.M. Swanson, N.H. Oberlies, Cytotoxic homoisoflavones from the bulbs of Bellevalia eigii, J. Nat. Prod. 78 (2015) 1708‑1715.

[7] X. Zhou, Z. Yuping, H. Zhao, J. Liang, Y. Zhang, S. Shi, Antioxidant homoisoflavonoids from Polygonatum odoratum, Food Chem. 186 (2015) 63‑68.

[8] Jordanian Fifth National Report under the Convention on Biological Diversity, Ministry of Environment, Amman, Jordan, 2014.

[9] N. Feinbrun-Dothan, Flora Palestina, The Israel Academy of Sciences and Humanities, Jeruselum, 1986.

[10] D.M. Al-Eisawi, Field Guide to Wild Flowers of Jordan and Neighbouring Contries, Jordan, Jordan Press, Foundation Al-Rai, Amman, 1998, pp. 1‑2.

[11] D. Al- Eisawi, Vegetation of Jordan, UNESCO, Cairo office1996.

[12] F.Q. Alali, C.S.M. Amrine, T. El-Elimat, A. Alkofahi, K. Tawaha, M. Gharaibah, S.M. Swanson, J.O. Falkinham III, M. Cabeza, A. Sánchez, M. Figueroa, N.H. Oberlies, Bioactive withanolides from Withania obtusifolia, Phytochem. Lett. 9 (2014) 96‑101.

[13] F.Q. Alali, T. El-Elimat, C. Li, A. Qandil, A. Alkofahi, K. Tawaha, J.P. Burgess, Y. Nakanishi, D.J. Kroll, H.A. Navarro, J.O. Falkinham, M.C. Wani, N.H. Oberlies, New colchicinoids from a native Jordanian meadow saffron, Colchicum brachyphyllum: isolation of the first naturally occurring dextrorotatory colchicinoid, J. Nat. Prod. 68 (2005) 173‑178.

[14] F.Q. Alali, A. Gharaibeh, A. Ghawanmeh, K. Tawaha, N.H. Oberlies, Colchicinoids from Colchicum crocifolium Boiss.: a case study in dereplication strategies for (−)-colchicine and related analogues using LC-MS and LC-PDA techniques, Phytochem. Anal. 19 (2008) 385‑394.

[15] H. Taifour, A. El-Oqlah, Jordan Plant Red List, Royal Botanic Garden, Amman, Jordan, 2014.

[16] D.M. Al-Eisawi, Field Guide to Wild Flowers of Jordan and Neighbouring Countries, Jordan Press Foundation Al Rai, Amman, 1998.

[17] J. Rae, C. Creighton, J. Meck, B. Haddad, M. Johnson, MDA-MB-435 cells are derived from M14 melanoma cells‑a loss for breast cancer, but a boon for melanoma research, Breast Cancer Res. Treat. 104 (2007) 13‑19.

[18] T. El-Elimat, M. Figueroa, H.A. Raja, S.M. Swanson, J.O. Falkinham, D.M. Lucas, M.R. Grever, M.C. Wani, C.J. Pearce, N.H. Oberlies, Sorbicillinoid analogues with cytotoxic and selective anti-Aspergillus activities from Scytalidium album, J. Antibiot. 68 (2015) 191‑196.

[19] T. El-Elimat, H.A. Raja, J.O. Falkinham, C.S. Day, N.H. Oberlies, Greensporones: Resorcylic acid lactones from an aquatic Halenospora sp, J. Nat. Prod. 77 (2014) 2088‑2098.

[20] M. Adinolfi, G. Barone, M. Belardini, R. Lanzetta, G. Laonigro, M. Parrilli, Homoisoflavanones from Muscari comosum bulbs, Phytochemistry 24 (1985) 2423‑2426.

[21] G. Amschler, A.W. Frahm, A. Hatzelmann, U. Kilian, D. Müller-Doblies, U. Müller-Doblies, Constituents of Veltheimia viridifolia; I. Homoisoflavanones of the bulbs, Planta Med. 62 (1996) 534‑539.

[22] M. Adinolfi, G. Barone, M.M. Corsaro, L. Mangoni, R. Lanzetta, M. Parrilli, Absolute configuration of homoisoflavanones from Muscari species, Tetrahedron 44 (1988) 4981‑4988.